An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

The Invasive Fungal Infection (IFI) market is witnessing a transformative shift driven by innovative solutions aimed at combating these pervasive threats to human health. With a growing incidence of ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...